The Technical Analyst
Rapt Therapeutics Inc [RAPT]
Exchange: NasdaqGM Sector: Healthcare Industry: Biotechnology
Rapt Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-0.99% $18.07
Last updated: 3 jul 2022 - 20:47
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 535.72 mill |
| EPS: | -2.56 |
| P/E: | 0.000 |
| Earnings Date: | Aug 09, 2022 |
| SharesOutstanding: | 29.65 mill |
| Avg Daily Volume: | 0.373 mill |
| RATING 2022-07-01 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$18.95 (4.85%) $0.877 |
| Date: 2022-07-04 |
| True Range Average |
|---|
|
+/- $1.422 ( +/- 7.87%) Range: 16.65 - 19.49 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-25 | Column Group Ii, Lp | Buy | 63 | Common Stock |
| 2022-05-25 | Column Group Ii, Lp | Buy | 1 837 | Common Stock |
| 2022-05-25 | Robbins Wendye | Buy | 8 500 | Stock Option (right to buy) |
| 2022-05-25 | Rieflin William Jl | Buy | 8 500 | Stock Option (right to buy) |
| 2022-05-25 | Lyons-williams Lori | Buy | 8 500 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 77.82 |
| Last 100 transactions |
| Buy: 1 891 233 | Sell: 253 079 |
Forecast:
16:00 - $18.07
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $18.07
Forecast 2: 16:00 - $18.07
Forecast 3: 16:00 - $18.07
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $18.07 (-0.99% ) |
| Volume | 0.132 mill |
| Avg. Vol. | 0.373 mill |
| % of Avg. Vol | 35.42 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RAPT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since 31-12-69
| Date | Signal | @ | Closed | % | Jun 28 - 16:58 | buy | $18.02 | N/A | Active |
|---|
RAPT
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 64 full-time employees. The company is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. The company has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.
Latest Press Releases
2022-05-25 08:00:00 - Press Release
Rapt Therapeutics Announces Private Placement Financing Of $50 Million
South san francisco, calif., may 25, 2022 (globe newswire) -- rapt therapeutics, inc. (nasdaq: rapt), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced a $50 million private investment in public equity (pipe) financing from the sale of pre-funded warrants to purchase up to 4 million shares of its common stock at a price per pre-funded warrant of $12.4999 to redmile group, based on the closing price per share of rapt on may 24, 2022. gross proceeds from the pipe financing total approximately $50 million, before deducting offering expenses...
2022-05-23 08:00:00 - Press Release
Rapt Therapeutics Announces Initiation Of Phase 2b Trial Of Rpt193 In Patients With Moderate-to-severe Atopic Dermatitis
South san francisco, calif., may 23, 2022 (globe newswire) -- rapt therapeutics, inc. (nasdaq: rapt), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it has initiated its 16-week randomized, double-blind, placebo-controlled phase 2b clinical trial to further evaluate the efficacy and safety of rpt193 as monotherapy in patients with moderate-to-severe atopic dermatitis (ad).
2022-05-11 08:00:00 - Press Release
Rapt Therapeutics Reports First Quarter 2022 Financial Results
Company maintains strong cash position of $173.0 million company maintains strong cash position of $173.0 million
2022-05-04 08:00:00 - Press Release
Rapt Therapeutics Expands Leadership Team With Multiple Key Hires
South san francisco, calif., may 04, 2022 (globe newswire) -- rapt therapeutics, inc. (nasdaq: rapt), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointments of gwen carscadden as chief human resources officer, jim farmer as vice president of clinical operations and shari geffon as vice president of program and alliance management.
2022-03-28 08:00:00 - Press Release
Rapt Therapeutics Announces Biomarker Data From Phase 1b Trial Of Rpt193 Consistent With Disease Modification In Atopic Dermatitis
Significant improvement in atopic dermatitis gene signatures in patients treated with rpt193 reported in late-breaking presentation at the american academy of dermatology annual meeting significant improvement in atopic dermatitis gene signatures in patients treated with rpt193 reported in late-breaking presentation at the american academy of dermatology annual meeting
Latest News
2022-05-11 10:32:07 - Zacks Investment Research
Rapt Therapeutics (RAPT) Reports Q1 Loss, Tops Revenue Estimates
Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -4.55% and 60.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-01-04 08:00:00 - GlobeNewsWire
RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9:00 a.m. ET.
2021-11-10 19:50:12 - Zacks Investment Research
Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates
Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -5.00% and -33.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-11-08 16:06:08 - Zacks Investment Research
Rapt Therapeutics (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Rapt Therapeutics (RAPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2021-10-18 08:00:00 - GlobeNewsWire
RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that it will present additional clinical efficacy data from its Phase 1b monotherapy trial of RPT193 in patients with moderate-to-severe atopic dermatitis at the 4th Inflammatory Skin Disease Summit to be held November 3-6, 2021 in New York, NY.
2021-09-30 09:15:00 - GlobeNewsWire
RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD) were presented at the European Academy of Dermatology and Venereology (EADV) Congress by Robert Bissonnette, M.D., FRCPC. Dr. Bissonnette is a board-certified dermatologist and currently serves as president of the board of directors of the International Eczema Council...
2021-09-03 08:00:00 - GlobeNewsWire
RAPT Therapeutics to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the following investor conferences in the first half of September:
2021-06-18 12:24:00 - GlobeNewsWire
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the closing of its previously announced underwritten public offering of 4,356,060 shares of its common stock at a price to the public of $33.00 per share, which includes 568,181 shares issued and sold upon full exercise of the underwriters' option to purchase additional shares of common stock. All of the shares of common stock were offered by RAPT. The aggregate gross proceeds to RAPT from the offering were approximately $143...
2021-06-16 12:47:19 - Zacks Investment Research
RAPT Reports Positive Data From Atopic Dermatitis Study
RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.
2021-06-15 23:07:00 - GlobeNewsWire
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its previously announced underwritten public offering of 3,787,879 shares of its common stock at a price to the public of $33.00 per share. All of the shares of common stock are being offered by RAPT. Gross proceeds to RAPT from the offering are expected to be approximately $125 million, before deducting underwriting discounts and commissions and estimated offering expenses...